Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 11/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715006 | 0.93 | EDNRA (0.52) | EDNRAHDAC1BRD4 | |
| SCHEMBL6781503 | 0.92 | EDNRA (0.49) | EDNRA | |
| SCHEMBL6724931 | 0.89 | EDNRA (0.62) | EDNRAHDAC1 | |
| SCHEMBL6718224 | 0.89 | EDNRA (0.49) | EDNRAHDAC1BRD4 | |
| SCHEMBL6716520 | 0.88 | EDNRA (0.56) | EDNRAHDAC1 | |
| SCHEMBL6717710 | 0.84 | EDNRA (0.64) | EDNRAHDAC1 | |
| SCHEMBL6714977 | 0.82 | GSPT1 (0.45) | EDNRA | |
| SCHEMBL7209077 | 0.81 | MAPK10 (0.43) | — | |
| SCHEMBL6720416 | 0.80 | EDNRA (0.53) | EDNRA | |
| SCHEMBL6714964 | 0.80 | SGK1 (0.49) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
| EP-1337515-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002040450-A1 | (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | EDNRA 639/4885HDAC1 500/4885BRD4 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.